Skip to main content
. 2018 Nov 14;10:773–790. doi: 10.2147/CEOR.S178934

Figure 3.

Figure 3

Probabilistic sensitivity analysis results (without price parity between the two CDK4/6 inhibitors), represented through an incremental cost-utility plane (A) and a cost-effectiveness acceptability curve (B)

Abbreviations: CDK4/6, cyclin-dependent kinase 4 and 6; LZE, letrozole; QALY, quality-adjusted life year.